Streetbeat News

Products Services

NVAX

Novavax received FDA approval to resume testing its combination COVID-19-flu and standalone flu vaccines, leading to a slight increase in its stock price.

Portfolio Pulse from

November 11, 2024 | 6:45 pm

LCID

Lucid's stock is experiencing a rise as its flagship electric vehicle, the Air sedan, is being tested by a police agency.

Portfolio Pulse from

November 11, 2024 | 6:30 pm

TTD

The Trade Desk's Q3 2024 results show strong customer retention and increased usage of UID2, potentially boosting the stock.

Portfolio Pulse from

November 11, 2024 | 6:30 pm

PARA

Paramount Global's third-quarter 2024 financial results show a mixed performance, with revenue down. However, analysts remain optimistic about future releases like 'Gladiator II' and 'Sonic 3' potentially boosting the company's performance.

Portfolio Pulse from

November 11, 2024 | 6:30 pm

INSG

Inseego (INSG) is set to report its Q3 earnings, with expectations of positive performance driven by growth in 5G markets and ongoing product and service development.

Portfolio Pulse from

November 11, 2024 | 6:30 pm

RYCEY

Rolls-Royce's recent trading update shows progress in power systems and new markets, with a positive forward P/E outlook. Supply chain challenges pose a risk to its civil aerospace segment, but are currently controlled.

Portfolio Pulse from

November 11, 2024 | 6:30 pm

ACHC

CYH

HCA

THC

UHS

The Zacks Medical-Hospital industry is expected to benefit from increasing patient admissions and technological advancements. Companies such as HCA Healthcare, Tenet Healthcare, Universal Health Services, Acadia Healthcare, and Community Health Systems are well-positioned to capitalize on these trends.

Portfolio Pulse from

November 11, 2024 | 6:30 pm

TRMB

Trimble has launched a free version of its ProjectSight software, incorporating AI and advanced tools to enhance construction project management. This move aims to make these capabilities accessible to contractors of all sizes, promoting automation and efficiency.

Portfolio Pulse from

November 11, 2024 | 6:15 pm

CRSP

VRTX

CRISPR Therapeutics reported no Q3 revenue from its Casgevy therapy, but remains optimistic due to promising results in treating genetic diseases and a strong cash position. The company continues to advance its pipeline, with support from Vertex.

Portfolio Pulse from

November 11, 2024 | 6:15 pm

ABBV

AbbVie's stock fell sharply after its schizophrenia drug Emraclidine failed to meet key objectives in Phase 2 clinical trials.

Portfolio Pulse from

November 11, 2024 | 6:00 pm